

NAM PUBLICATIONS
(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING
A SHARE CAPITAL)
UNAUDITED
TRUSTEES' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

**NAM PUBLICATIONS
(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)
CONTENTS**

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Mission Statement and Introduction from NAM's Chair and Executive Director	2
Trustees' Report	3 - 13
Independent Examiner's Report	14
Statement of Financial Activities	15
Balance Sheet	16
Statement of Cash Flows	17
Notes to the Financial Statements	18 - 34

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2021

Trustees	Tom Abell, Chair Brian Cooper, Vice chair Julia Reidy, Treasurer Dr Margaret Swain Dr Sanjay Bhagani Dr Julianne Lwanga Jason Schroen
Company registered number	02707596
Charity registered number	1011220
Registered office	Cally Yard 439 Caledonian Road London N7 9BG
Principal operating office	Cally Yard 439 Caledonian Road London N7 9BG
Company secretary	Matthew Hodson
Independent examiner	Marc Levy FCA
Accountants	Blick Rothenberg Limited Chartered Accountants 16 Great Queen Street Covent Garden London WC2B 5AH
Bankers	National Westminster Bank Plc 504 Brixton Road London SW9 8EB
Executive director	Matthew Hodson
Managing Editor	Roger Peabody

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

MISSION STATEMENT AND INTRODUCTION FROM NAM'S CHAIR AND EXECUTIVE DIRECTOR FOR THE YEAR ENDED 31 DECEMBER 2021

Our Mission: NAM provides independent, accurate and accessible information about HIV.

Our Vision: A world where HIV is no longer a threat to health or happiness.

Message from NAM's Chair of the Board of Trustees

This is my first message since becoming Chair of NAM and I wanted firstly to recognise and thank my predecessor, Margaret Swain, who has led the Trustees and the organisation so effectively.

The past year has been one where we have continued to see NAM making its presence felt, across the country and internationally through its continued conference and news reporting, alongside continuing to scale up the exciting new ways of engaging with others such as our strengthening social media presence and our aidsmapCHAT series.

I believe there probably has been never more need for independent, unbiased information and reporting as there is now – and the Trustees are committed to continuing this mission. I am excited that we have developed our new strategy, and our minds can now turn about how we deliver successfully on it for those that rely on us. As part of our work we will be reviewing our skill mix across the Trustees with a view to commencing recruitment during 2022 to strengthen the Board further.

I'd like personally to thank all of our Trustees who continue to go above and beyond to support the work of NAM, and on behalf of all of the Trustees I'd like to thank everyone who has supported us over the past year.

Finally, I would like to thank all of our people who've continued to adapt and respond to the challenges of the ongoing pandemic, under the great leadership of Matthew Hodson our Executive Director.

Tom Abell

Chair, NAM Publications

Date:

Message from NAM's Executive Director

Every week NAM's Managing Editor, Roger Pebody, convenes a meeting with our writers and staff members where we review abstracts from scientific journals to select the stories that will appear on the aidsmap site. As we adjust to new ways of remote working, necessitated by the COVID-19 pandemic, the number of participants at these meetings has grown. We have welcomed the fresh insights of new writers, recruited through our Emerging Voices programme, that reflect the diversity of experience of people living with or affected by HIV. Our meetings include writers from Asia, Africa, the Americas as well as Europe; they include people who acquired HIV during sex, or from drug use or who were born with the virus. That diversity of experience makes these meetings vibrant and visceral. I am dazzled by the insight that is shared and lifted by the passion to support people living with HIV, wherever they may live, whatever their circumstances. The energy in those meetings powers through the organisation and all of the services that we provide.

With funding challenges, failures in healthcare systems, further exacerbated by the global pandemic, and the persistent prevalence of stigma, we remain frustratingly far from realising NAM's vision of a world where HIV is no longer a threat to health or happiness. However, I am frequently honoured to hear from individuals how much NAM aidsmap has supported them. Many times I have been told that our accessible information has led to changes, in thinking about treatment or in adjusting to a positive HIV diagnosis, that has been life-saving.

In 2021 I was invited to co-Chair the European AIDS Conference, held in the city of my birth London. To the best of my knowledge, I am the first person openly living with HIV to take on such a role at an international medical conference but I am sure I will not be the last. Within HIV the power of the patient community, and the collaboration between us and our healthcare providers, has not just changed the way that HIV is treated, in many regions it has changed the way that healthcare is provided. NAM, with its foundations planted firmly in the community activism that led to its founding, 35 years ago, straddles these groups, those who provide HIV care and support and those who receive, recognising that many belong to both groups.

I feel it as an honour, as someone who is living with HIV, to play a leading role in an organisation that fights for the health and for the rights of people living with HIV the world over, that stands with all people who live with HIV against the challenges that this virus, and attitudes towards it, present. It is a privilege to be a part of an organisation that delivers this information. It is exciting to be among the very first to report on new medical and scientific innovations that may well transform the ways we prevent and treat HIV. The United Kingdom has set itself a goal of ending new HIV transmissions within the country by 2030. The goal is ambitious but it is also achievable, with the right level of support and resource. Other countries and regions are adopting similar ambitious goals. The end to this epidemic is imaginable. NAM has its role to play. We rise to meet the challenge.

DocuSigned by:

Matthew Hodson

13218886BDA547B...

Matthew Hodson

Executive Director, NAM Publications

Date: 21-Oct-22 | 08:45 EDT

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2021

The trustees present their annual report together with the financial statements of the charity for the year to 31 December 2021. The Annual Report serves the purposes of both a trustees' report and a directors' report under company law. The Trustees confirm that the Annual Report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective January 2019).

Since the charity qualifies as small under section 382 of the Companies Act 2006, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

In this report and elsewhere NAM Publications may sometimes be referred to by the abbreviated form, NAM, or with reference to one of its principal resources, NAM aidsmap.

Objectives and activities

Throughout 2021, the charity's objective, and its principal activity, continued to be the relief of sickness, hardship and distress among people with AIDS, HIV and related diseases and conditions, including but not limited to hepatitis. NAM also aims to advance the education of the public, including people working with those suffering from, or at risk of being affected by, such diseases and conditions.

There are no significant restrictions in the way the charity can operate and there have been no updates to the articles of the charity. Internal policies have been updated to reflect changes in relevant legislation.

The charity's mission throughout 2021 was to support the fight against AIDS with independent, accurate, accessible and comprehensive information. The charity aims to create and disseminate information resources rooted in the experience of those most affected, enabling individuals and communities to take action and control in responding to HIV and AIDS.

At the end of the year a new strategy was developed which was formally adopted early in 2022. NAM's mission, which has always been the core of our activity, is to provide independent, accurate and accessible information about HIV.

NAM's main area of activity is the production and dissemination of accurate and reliable information about HIV in a variety of formats to meet the needs of diverse audiences.

NAM's main beneficiaries are:

- People living with HIV.
- People at risk of or affected by HIV.
- People working in HIV, associated health conditions or with communities that have high HIV prevalence (including clinicians and other healthcare workers, researchers, prevention and public health specialists, policymakers, community advocates, activists and service providers).

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

NAM's strategy

In 2017 NAM adopted a new strategy to broaden our audience and increase our impact. This strategic direction has supported NAM's wider use of social media and digital video to bring information about HIV treatment, prevention and support to larger audiences.

Although the strategy was due to be reviewed in 2020, the uncertainty precipitated by the COVID pandemic led NAM's Trustees to instead revise the existing strategy, reflecting concerns which COVID had brought to the fore, while developing a new strategy for 2022 – 2025, which was adopted in 2022.

Interim strategy 2020 – 2021: Broadening our audience/ Increasing our impact

Reach greater and more diverse audiences.

We will do this by:

- Exploring and utilising new platforms for delivering information.
- Increasing NAM's public profile.
- Seeking opportunities to be pro-active in providing information.
- Reflecting the diversity of our current and potential service users.

Increasing our impact.

We will do this by:

- Pro-actively seeking new partnerships and collaborations, both within and outside of the HIV sector.
- Working collaboratively with agencies involved in conditions related to co-morbidities.
- Building partnerships with agencies involved in HIV & hepatitis policy and services.
- Supporting individual activists and advocates with provision of practical and reliable information.
- Adapting our provision of resources to meet the needs of people living with HIV during the COVID-19 pandemic.

Monitoring and evaluating our impact.

We will do this by:

- Setting outcome measures.
- Gathering feedback from our service users.
- Collecting and utilising insight from service users and potential service users in the development of new resources.

NAM is committed to ensuring the information we produce is:

- Accurate
- Accessible
- Clearly communicated
- Evidence-based
- Independent
- Up to date
- Relevant
- Rooted in the experiences of those most affected by HIV.

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

Achievements and performance in 2021

People who are informed, equipped and empowered are able to make better choices to support their own health. In the second year of a global pandemic, the need for clear, reliable and accessible information for people with HIV was more pronounced than ever. NAM aidsmap adapted the way that we deliver some of our services and created new resources to ensure that our audiences remained informed. In the process we reached more people with vital HIV information than at any other period in our history.

The aidsmap site remains the spine of our information provision but we have utilised and developed our skills to deliver workshops and a range of digital media projects online, through our own websites, social media and other platforms. In this way, in addition to the millions of visits to the aidsmap website, we also provided vital information about HIV and AIDS to millions of people on other platforms.

Providing appropriate, accurate and accessible information for people living with HIV about COVID-19 and the safety and efficacy of COVID vaccinations became a major theme of our work this year, responding to demand. NAM aidsmap's COVID content included 75 original news stories, videos, panel discussions and social media assets.

aidsmap

The aidsmap site is NAM's primary means of providing information to our audiences around the world.

The site was revamped in 2019 and in 2021 we saw a significant rise in traffic to the site, falling just short of an average half a million visits per month – almost a 40% increase in visits since 2019.

Our most popular information pages looked at estimated HIV risk for different exposure routes, the variation in window periods for different HIV tests and life expectancy for people living with HIV. Towards the end of the year we supplemented these pages with talking heads videos, also shared on social media, making the most sought for information accessible for larger audiences.

The COVID pandemic meant that many people living with HIV urgently required tailored accurate information (for example, about vaccine safety and efficacy for people with HIV, about the severity of illness or vulnerability to infection). COVID related stories were among the most widely read on our news pages, demonstrating the valuable support that the aidsmap site provides in challenging times.

Bulletins

Our bulletins get information directly to the people who need news and information about HIV.

aidsmap news - provides treatment news particularly targeted and appropriate for healthcare providers and others professionally involved with HIV. Bulletins signpost in depth content on the site, helping healthcare providers deliver a better experience of care for people living with HIV.

The aidsmap news bulletin now has 49,939 subscribers.

HIV Update - provides clear, accessible information particularly targeted and appropriate for people living with HIV.

The HIV update bulletin now has 39,335 subscribers.

The Eurobulletin – a quarterly bulletin which provides information about policies, programmes, standards, guidance, evidence and research, and emerging issues in sexual and reproductive healthcare, HIV treatment and care, prevention and sexual health promotion.

The Eurobulletin has 811 subscribers.

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

Conference reporting

In 2021 NAM aidsmap reported from HIV Research for Prevention (R4P), Conference on Retroviruses and Opportunistic Infections (CROI), the fifth Joint Conference of the British HIV Association with the British Association of Sexual Health and HIV ((BHIVA and BASSH), the 11th International AIDS Society Conference on HIV Science (IAS), all of which were held virtually, and the European AIDS Conference (EACS) which was a hybrid conference, hosted in London and co-chaired by NAM trustee Dr Sanjay Bhagani and NAM's Executive Director, Matthew Hodson, alongside Dr Anne-Marie Wensing of the Netherlands.

aidsmapLIVE

In 2021 NAM presented three editions of the award-winning aidsmapLIVE, hosted by NAM team member Susan Cole.

These panel discussions were all virtual in 2021, enabling us to gather together experts and activists from around the world to discuss key topics for people living with HIV and those who care for us.

These broadcasts are viewed around the world and the audience are able to interact with the panel via social media.

The 2021 editions of the show focussed on:

- Health inequalities and HIV
- Stories and research from the International AIDS Society Conference
- HIV Prevention

All episodes of aidsmapLIVE remain available to view on YouTube and on the aidsmap site.

aidsmapCHAT

aidsmapCHAT completed its 3rd season of 6 episodes in the early months of 2021 and then returned in the summer months for a 4th season. Hosted by NAM's Susan Cole and Matthew Hodson, the show features a diverse range of international community experts, policy-makers, politicians, researchers and clinicians as guests.

Guests in 2021 included Linda-Gail Bekker Director of the Desmond Tutu Institute and former President of the International AIDS Society, former and current Chairs of the British HIV Association, Chloe Orkin and Laura Waters, human rights campaigner Peter Tatchell, Head of HIV at the CDC Demetre Daskalakis and a special studio recorded edition of the show with the head of UNAIDS, Winnie Byanima.

aidsmapWOMEN

The third part of the three-part series was broadcast in February, highlighting the experience, expertise and resilience of women, living with or affected by HIV, hosted by Susan Cole and supported by Dr Vanessa Apea.

PrEP in Europe

PrEP in Europe (PEI) was a community-led partnership with HIV organisations across Europe, working to increase awareness of and access to HIV pre-exposure prophylaxis (PrEP) through co-ordinated advocacy across the entire WHO Europe region.

In 2021 PrEP in Europe hosted a webinar for educators and advocates on the latest PrEP research and developments (injectables, long acting etc.) as well as two webinars on PrEP for women. NAM supported our partners across Europe with HIV prevention news and resources, providing presentations and briefings to healthcare professionals to further the case for PrEP and its efficacy.

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

PrEP in Europe (continued)

With PrEP access now granted across almost all of Western Europe the partners agreed that that the initial goals had been largely met and new approaches and partnerships may be required for the remaining challenges (ensuring all groups at high risk of HIV acquisition are aware of PrEP and can access it; ensuring PrEP access in countries that still do not provide it, particularly in Eastern Europe).

HIV information videos

Aidsmap Information videos: Following the success of the aidsmap U equals U video, NAM created five new information videos on 'How HIV is transmitted', 'Life expectancy', 'HIV testing window periods', 'Feeding your baby when you're living with HIV' and 'COVID-19 vaccines for people living with HIV'. Each of these videos have racked up thousands of views across social media platforms and continue to be shared.

Positive Champions: NAM, working in partnership with Africa Advocacy Foundation, produced 10 videos of people from African communities living with HIV talking about the benefits of testing.

GROWS project: NAM, working in partnership with the Sophia Forum, Positively UK and UCL institute for Global Health produced seven videos for women living with HIV, growing older, wiser and stronger.

Family Matters: NAM, working in partnership with the 4M Network of Mentor Mothers produced three videos about conception, pregnancy, childcare and beyond for women living with HIV.

UK AIDS Memorial Quilt display: NAM was commissioned by The Food Chain to create a video sharing stories from the UK quilt, on display in its entirety for the first time since 1994. This video came in a short version for sharing on social media and an extended version for the aidsmap site, YouTube and other platforms.

NAM Patient Information Resources

In addition to our online resources NAM published a new edition of the HIV and Sex booklet, with both print and online versions available for members of NAM's Clinic Scheme. The new booklet provides clear accessible information on sex and sexual safety for people living with HIV, clearly sharing the information that when people with HIV are virally suppressed on treatment there is no risk of sexual transmission.

Community Engagement

This project supports people across the UK to live well with HIV, by developing new and innovative ways of engaging people living with, or at high risk of acquiring HIV with information relating to treatment, support and prevention. Following the move to more remote working precipitated by COVID last year our community engagement sessions remained online and were able to reach more people than ever before.

Our Community Engagement programme works directly with people living with HIV all across the UK, with particular success in reaching people from BAME communities, and women.

HIV Lens

HIV Lens is an interactive online mapping tool that visualises the impact of HIV epidemic on communities across England. The site is a collaboration between NAM and Watipa with support from Gilead Sciences.

This website presents information about HIV services and statistical data on HIV prevalence, incidence, testing and key populations, drawn from Public Health England. Data are accessible at different geographic levels which users of the site may use to plan effectively, compare how they are doing in relation to other areas and improve their services or policies.

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

Tell Me About It

NAM produced a short series of podcasts, Tell Me About It, inspired by the conversations that people living with HIV often find themselves having with those unaware of the many new and life-changing developments in HIV prevention and treatment – how did you get it? Aren't you just a drain on NHS resources? Can I catch it off you? Will you die young? These everyday conversations can be an opportunity for education, given that there are significant gaps between public perceptions, and the lived experience of those with diagnosed HIV.

Hosted by writer, researcher, international performance poet and TEDx speaker Bakita Kasadha, each episode is a conversation between people sharing their experiences of living with HIV, or opening up about their assumptions and what they'd love to know more about.

infohep

infohep provides news, conference reporting and bulletins relating to hepatitis, primarily through the infohep website. These news stories and bulletins provide accessible and reliable information, advancing awareness of viral hepatitis, and increase knowledge of the condition enabling people to make more informed choices about treatment and care.

In 2021 we published 61 original news stories on Infohep, which had 32,000 website visits. The infohep bulletins were sent to 3,200 subscribers.

Emerging Voices

As part of our strategic commitment to ensuring that we reflect the diversity of our service users NAM created a mentoring programme to support new writers, particularly from communities that are underrepresented in scientific reporting. Emerging Voices gives new writers the opportunity to gain experience and develop their skills in a professional and supportive environment, providing them with paid opportunities to develop their skills and support people living with HIV.

In 2021, we were able to recruit five new writers to the scheme, support another seven to further develop their skills, and enable two participants to graduate from the scheme, becoming regular freelance writers for NAM. In 2021 the Emerging Voices scheme expanded internationally, bringing in new writers from Southern Asia and sub-Saharan African nations, enriching aidsmap's new coverage with fresh perspectives.

The programme has brought new talent into the editorial team. Several writers who came to NAM via the Emerging Voices programme are now regular freelance contributors to the site. The programme has contributed to NAM's strategic aim to reflect the diversity of our current and potential service users.

Social Media

Social media platforms, including Facebook, Twitter, Instagram, YouTube and WhatsApp play an ever-growing part of the way that people access and engage with information. aidsmap's news stories are always shared on the major platforms, and our digital projects, such as aidsmapLIVE and aidsmapCHAT use Facebook and Twitter as their primary platforms.

NAM's use of social media and a range of digital platforms supports our strategic goals of utilising new platforms for delivering information, increasing NAM's public profile and being pro-active in providing information.

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

NAM aidsmap in the news

NAM's expertise was enlisted by specialist and mainstream media to speak about COVID vaccine safety for people living with HIV, the hit Channel 4 drama series, It's A Sin, long-acting injectable HIV treatment, targets for ending HIV infections and other HIV related news stories of the year.

Increasing NAM aidsmap's profile was a part of the 2017-2021 strategy, in order to increase awareness of the information services that we offer.

NAM's Executive Director was co-chair of the 2021 European AIDS Conference, held in London, and NAM's Susan Cole delivered a speech as part of the closing plenary session for the 2021 International AIDS Society Conference.

Future plans

At the end of 2021 NAM's Trustee and staff attended a facilitated meeting to develop a new strategy, which was adopted at the beginning of 2022.

The new strategy refined NAM's mission and articulated for the first time NAM's vision and principles.

This strategy is intended to take NAM through to 2025.

Our Mission: NAM provides independent, accurate and accessible information about HIV.

Our Vision: A world where HIV is no longer a threat to health or happiness.

Our Principles:

- Independent, accurate and accessible information is vital in the fight against HIV and AIDS.
- Knowledge empowers and equips people to manage their health.
- Knowledge enables advocates, campaigners and communities to take action on health.
- The information we provide should help our audiences effect change in their own lives, their work or their communities.
- Reducing HIV stigma removes barriers to testing and treatment.
- Social inequalities must be addressed to deliver health equality.
- We strive to serve individuals, communities and providers across the world, recognising that needs and culture differ.

Our audiences:

- People living with HIV.
- People at risk of or affected by HIV.
- People working in HIV, associated health conditions or with communities that have high HIV prevalence (including clinicians and other healthcare workers, researchers, prevention and public health specialists, policymakers, community advocates, activists and service providers).

The ability to treat and prevent HIV is progressing rapidly.

NAM will continue to provide scientifically accurate information on prevention, treatment and cure, with a focus on emerging issues and new technologies.

Many international agencies, nations and organisations have committed to end new HIV infections and AIDS deaths by 2030.

NAM will support efforts to meet these targets through the provision of clear and accurate information to inform policy and practice.

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

The HIV epidemic is not over until it is over in all regions and communities.

NAM will deliver relevant HIV information to populations with high need, seeking to work in collaboration with local individuals and organisations.

HIV stigma creates barriers to testing and treatment and also impacts upon the emotional health of people living with HIV.

NAM will proactively challenge stigma through the creation of accessible resources highlighting, for example, the impact of HIV treatment on life-expectancy and transmission.

COVID and other health concerns create ongoing challenges for people living with HIV.

NAM will address the information needs of people living with HIV about COVID and other health concerns.

HIV affects diverse communities.

NAM will respond to the diversity of need, experience and situation of those who may benefit from our work by presenting information in a variety of formats and on multiple platforms to reach broad audiences.

The needs and experience of people with HIV intersect with other inequalities and inequities.

NAM's work will be informed by the understanding that needs are often intersectional and we will seek to empower those who are marginalised.

Financial review

The Trustees have considered the charity's cash flow forecast for the period ahead and are confident given the cash flow forecast and the charity's unrestricted funds that the charity remains viable over at least 12 months. Accordingly, the Trustees have continued to adopt the going concern basis in the preparation of the financial statements.

Reserves policy

The charity continues to operate in an uncertain funding climate in which it is difficult to estimate when and whether grants and consultancy income will be received, and it is not uncommon for grants to be unexpectedly delayed. Because of these uncertainties, it is necessary for the charity to hold reserves to cover expenditure in the event of a shortfall of income. In a worst-case scenario of charitable income suffering a disastrous decline, it would be necessary to cease operations and the trustees hold reserves to enable an orderly winding up to take place.

To allow for the eventualities described above, it is the trustees' present policy to hold free unrestricted reserves (i.e. excluding designated and restricted reserves) of not less than six months' running costs. At 31 December 2021 free reserves stood at £675,083 which was equivalent to 83% of projected total expenditure for 2022 and total reserves stood at £777,999. Although this is above the minimum level of the policy, the trustees consider it prudent to hold reserves at this level in view of the continued unstable charity funding climate. It should be noted that the holding of significant levels of free reserves has enabled the charity to continue to serve its beneficiaries.

Financial performance review

The Statement of Financial Activities shows a contribution to unrestricted funds of £67,183.

This surplus was larger than trustees had initially expected at the start of the year when the original budget anticipated a deficit. However, a number of our plans for 2021 were delayed due to the continuing impact of the covid pandemic. Firstly, with many clinics still closed or running at reduced capacity the printing and distribution of resource for people living with HIV was substantially reduced from our original budget projections. We had also planned to increase the capacity of our staff team with recruitment of a new full-time editor. During the course of the year dealing with a number of operational challenges as the organisation adjusted in response to the changing situation that the pandemic presented meant that the recruitment was postponed until early 2022. As well as some significant planned expenditure being deferred to 2022 there was some additional income in respect to miscellaneous consultancy projects that occurred towards the end of the year.

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

Financial performance review (continued)

Total income for 2021 at £731,550 was £74,427 lower than in 2020. Income for 2020 was unusually high due to the receipt of a substantial legacy. Total expenditure decreased by £23,148 however the reduction was mainly a result of activity being deferred into 2022.

Our restricted funds stood at £102,916 at the end of the financial year and will support projects in 2022. As unrestricted funds stood at £675,083 the total funds of the charity were £777,999 at 31 December 2021

NAM holds its surplus funds in deposit accounts of UK clearing banks.

NAM would like to thank all of our supporters over the year including:

- Compare the Cloud
- Gilead Sciences Europe
- Janssen Cilag
- Lloyds Pharmacy
- The London Community Fund
- Merck & Co
- Mercury Phoenix Trust
- National HIV Prevention Programme for England
- The National Lottery Community Fund
- North East London NHS CSU (Fast Track Cities)
- Public Health England
- Sophia Forum
- Theratechnologies
- ViiV Healthcare
- Wandsworth Oasis

In addition to the donors above we would also like to thank all our individual donors.

Structure, governance and management

NAM Publications is registered as a company limited by guarantee and not having a share capital. Throughout the year under review the company was ruled by, and complied with, its revised Articles of Association dated 7 February 2011.

NAM Publications is also registered as a charity with the Charity Commission.

Methods of appointment or election of trustees

NAM's Chair, Deputy Chair and Treasurer are elected by the trustees.
NAM's Chair, Dr Margaret Swain, was elected Chair in December 2017.
NAM's Deputy Chair, Tom Abell, was elected in October 2020.
NAM's Treasurer, Julia Reidy, was elected Treasurer in August 2019.

Trustees are recruited whenever a gap or deficit occurs in any of the following areas that are essential to NAM's successful operation: employment, finance, information provision, income generation, governance & management, asset management, external relations, quality standards and strategic implementation. Trustee recruitment may also occur whenever an opportunity arises to appoint an individual with a special combination of applicable experience, knowledge or skills; or when there is a sudden fall in board membership.

NAM PUBLICATIONS
(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)
TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Policies adopted for the induction and training of Trustees

New Trustees are first interviewed by representatives of the board and staff management team and invited to attend a trustees' meeting prior to appointment. Trustees are advised to engage with guidance for trustees provided by the Charity Commission. Should further training needs or appropriate opportunities arise these may be met from the organisation's dedicated training budget. NAM has recently updated its induction process for new trustees.

Risk management

The charity has a risk management strategy which comprises:

- a bi-monthly review of the risks the charity may face
- the establishment of systems and procedures to mitigate those risks that are identified by the review; and
- the implementation of measures designed to minimise any potential impact on the charity should those risks materialise

The Trustees believe that the principal risks and uncertainties facing the charity relate to concerns over the ability to build sufficient levels of income to cover all of the charitable expenditure.

Continuing efforts to diversify funding sources have had limited success and so the board has maintained high levels of free reserves to ensure continuation of delivery.

Members' liability

All of the Trustees are members of the company and guarantee to contribute £1 in the event of a winding up. None of the Trustees has any beneficial interest in the company.

Arrangements for the setting of key management remuneration

The pay for the Executive Director was set at their recruitment based on sector comparisons for charities of a similar size. The pay for the Managing Editor was set on their appointment to reflect the responsibilities and skills required for a specialist role within the charity. Annual cost of living increases have been awarded at the trustees' discretion based on overall affordability.

Organisational structure and decision making

NAM's Board of Trustees set the organisational strategy and entrust the Executive Director to operationalise it. The Executive Director reports to the trustees formally at Board meetings, held every other month and may also seek ad hoc advice if required.

The Executive Director directly line manages the Managing Editor, Business Manager, Website Editorial Manager, Community Engagement, Marketing and Membership Manager and Fundraising and Development Manager. The Managing Editor has line management responsibility for the HIV Information Editor. The Website Editorial Manager has line management responsibility for the Head of Design.

NAM PUBLICATIONS
(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)
TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Reference and administrative details:

Registered office: 439 Caledonian Rd, London N7 9BG
Principal office: 439 Caledonian Rd, London N7 9BG
Company limited by guarantee, registered in England & Wales, company number: 2707596 Registered charity number: 1011220

Trustees

The Trustees, who are also the directors for the purpose of company law, and who served during the year and since the year end were as follows:

Dr Margaret Swain	Chair since 5 December 2017 Stood down as Chair 3 February 2022 Appointed 11 December 2012 Re-appointed 2 February 2021
Tom Abell	Appointed Deputy Chair 6 October 2020 Re-appointed 3 February 2022 Chair since 1 February 2022
Julia Reidy	Appointed Treasurer 1 October 2019 Re-appointed 1 February 2022
Dr Sanjay Bhagani	Appointed 15 June 2015 Re-appointed 1 February 2022
Brian Cooper	Appointed 22 March 1999 Re-appointed 2 February 2021 Appointed Vice Chair 1 February 2022
Duncan Jarvies	Appointed 4 October 2016 Resigned 12 April 2022
Dr Julianne Lwanga	Appointed 15 December 2017 Re-appointed 2 February 2021
Jason Schroen	Appointed 12 April 2017 Re-appointed 2 February 2021

Small companies exemption

In preparing this report, the Trustees have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

Approved by order of the members of the board of trustees and signed on their behalf by:

DocuSigned by:



B149BB086A2D4B8...

Tom Abell

Chair
Date: 21-Oct-22 | 08:46 BST

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Independent Examiner's Report to the Trustees of NAM Publications ('the charity')

I report to the charity trustees on my examination of the financial statements of the charity for the year ended 31 December 2021, which are set out on pages 16 to 35.

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the company and the charity's trustees as a body, for my work or for this report.

Responsibilities and Basis of Report

As the trustees of the charity (and its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:

Dated:

Marc Levy FCA (ICAEW)

Blick Rothenberg Limited

Chartered Accountants

16 Great Queen Street

Covent Garden

London

WC2B 5AH

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2021**

	Note	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Income from:					
Donations and legacies:	3				
Donations		44,327	-	44,327	37,800
Legacies		10,000	-	10,000	150,000
Charitable activities:	4				
Provision of HIV treatment information		104,414	341,861	446,275	423,894
Provision of information on the treatment of hepatitis		15,000	19,903	34,903	11,990
Provision of information on testing, transmission, and prevention of HIV		150	53,536	53,686	91,263
Provision of social and non-clinical information		53,131	88,628	141,759	89,945
Investments	5	76	-	76	996
Other	6	524	-	524	89
Total income		227,622	503,928	731,550	805,977
Expenditure on:					
Raising funds	7	1,065	-	1,065	1,119
Charitable activities:	8				
Provision of HIV treatment information		106,293	366,289	472,582	481,867
Provision of information on the treatment of hepatitis		8,019	14,927	22,946	20,186
Provision of information on testing, transmission, and prevention of HIV		40,992	51,624	92,616	98,727
Provision of social and non-clinical information		4,070	64,378	68,448	78,906
Total expenditure		160,439	497,218	657,657	680,805
Net movement in funds		67,183	6,710	73,893	125,172
Reconciliation of funds:					
Total funds brought forward		607,900	96,206	704,106	578,934
Net movement in funds		67,183	6,710	73,893	125,172
Total funds carried forward		675,083	102,916	777,999	704,106

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 18 to 34 form part of these financial statements.

NAM PUBLICATIONS
(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

BALANCE SHEET
FOR THE YEAR ENDED 31 DECEMBER 2021

	Note	2021 £	2020 £
Fixed assets			
Tangible assets	13	11,856	5,894
		<u>11,856</u>	<u>5,894</u>
Current assets			
Debtors	15	49,693	297,834
Cash at bank and in hand		829,110	537,508
		<u>878,803</u>	<u>835,342</u>
Creditors: amounts falling due within one year	16	(112,660)	(137,130)
		<u>766,143</u>	<u>698,212</u>
Net current assets		766,143	698,212
Total assets less current liabilities		777,999	704,106
Total net assets		777,999	704,106
Charity funds			
Restricted funds	20	102,916	96,206
Unrestricted funds	20	675,083	607,900
		<u>777,999</u>	<u>704,106</u>
Total funds		777,999	704,106

The charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the trustees and signed on their behalf by:

DocuSigned by:

 B149BB086A2D4B8...
Tom Abell
 Chair

Date: 21-Oct-22 | 08:46 BST

The notes on pages 18 to 34 form part of these financial statements.

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2021**

	Note	2021 £	2020 £
Cash flows from operating activities			
Net cash used in operating activities	23	301,367	(29,003)
Cash flows from investing activities			
Interest received		76	996
Purchase of tangible fixed assets		(9,841)	-
Net cash (used in)/provided by investing activities		(9,765)	996
Cash flows from financing activities			
Net cash provided by financing activities		-	-
Change in cash and cash equivalents in the year		291,602	(28,007)
Cash and cash equivalents at the beginning of the year		537,508	565,515
Cash and cash equivalents at the end of the year	24	829,110	537,508

The notes on pages 18 to 34 form part of these financial statements

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021**

1. General information

NAM Publications is a charitable company limited by guarantee incorporated in England and Wales. The registered office is Cally Yard, 439 Caledonian Road, London, England, N7 9BG.

The financial statements are presented in Sterling (£), which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

2. Accounting policies**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) and the Companies Act 2006.

NAM Publications meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

The trustees have considered the charity's cash flow forecast for the period ahead. Notwithstanding the challenging funding environment due to the recovery from Covid, the implications of Brexit, the economic impact of the war in Ukraine and the cost of living crisis, the trustees believe that with careful management the charity has a reasonable expectation of having sufficient resources to continue in operation for the foreseeable future, this being 12 months from the date of approval of these financial statements. Accordingly, the trustees have continued to adopt the going concern basis in the preparation of the financial statements.

2.3 Income

Incoming resources are recognised in the period in which the charity is entitled to their receipt and the amount can be measured with reasonable certainty. Income is deferred only when the charity has to fulfil conditions before becoming entitled to it or where the donor or funder has specified that the income is to be used in a future accounting period.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the charity has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the charity, can be reliably measured.

Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the service.

Subscription income from publications is recognised evenly over the period to which the subscription relates.

Interest income is recognised when receivable and the amount can be measured reliably.

NAM PUBLICATIONS
(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required, and the amount of the obligation can be measured reliably. Expenditure is classified under the following headings:

- Costs of raising funds
- Expenditure on charitable activities
- Other costs not dealt with in the preceding headings.

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include staff costs, information technology costs, establishment costs and governance costs. These costs have been allocated between costs of raising funds and expenditure on charitable activities on a basis consistent with the use of resources, e.g. staff costs by time spent and other costs by estimated usage.

Expenditure on raising funds includes all expenditure incurred by the charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the charity's objectives, as well as any associated support costs.

2.5 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

At each reporting date the charity assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined to be the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives.

Depreciation is provided on the following basis:

Plant and machinery	-	25%	reducing balance
Fixtures and fittings	-	15%	on cost

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Statement of Financial Activities.

2.6 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

2.7 Financial instruments

The charity has elected to apply Sections 11 and 12 of FRS 102 in respect of financial instruments.

Financial assets and financial liabilities are recognised when the charity becomes party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

The charity's policies for its major classes of financial assets and financial liabilities are set out below.

Financial assets

Basic financial assets, including trade and other debtors and cash and bank balances are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

Financial liabilities

Basic financial liabilities, including trade and other creditors are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Impairment of financial assets

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the company would receive for the asset if it were to be sold at the reporting date.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in the statement of financial activities.

NAM PUBLICATIONS

(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

Financial instruments (continued)

Derecognition of financial assets and financial liabilities

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Offsetting of financial assets and financial liabilities

Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

2.8 Operating leases

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight-line basis over the lease term.

2.9 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2.10 Retirement benefits

The charity operates a defined contribution pension scheme for all qualifying employees and contributes to the personal pension plans of certain employees. The assets of the schemes are held separately from those of the charity in independently administered funds.

2.11 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes, name or funder of the restricted funds are set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021****2. Accounting policies (continued)****2.12 Company status**

The company does not have a share capital and the liability of its members is limited by guarantee to a maximum of £1 each.

The company satisfies the requirements of Section 60(1) of the Companies Act 2006 and having made a statutory declaration to this effect is exempt from using the word 'Limited' in its name.

3. Income from donations and legacies

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Donations and gifts	44,327	44,327	37,800
Legacies	10,000	10,000	150,000
	<u>54,327</u>	<u>54,327</u>	<u>187,800</u>
	<u><u>187,800</u></u>	<u><u>187,800</u></u>	
Total 2020			

4. Income from charitable activities

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Provision of HIV treatment information	104,414	341,861	446,275	423,894
Provision of information on viral hepatitis	15,000	19,903	34,903	11,990
Provision of information on HIV testing, transmission, and prevention of HIV	150	53,536	53,686	91,263
Provision of social and non-clinical information on HIV	53,131	88,628	141,759	89,945
Total 2021	<u>172,695</u>	<u>503,928</u>	<u>676,623</u>	<u>617,092</u>
Total 2020	<u><u>151,015</u></u>	<u><u>466,077</u></u>	<u><u>617,092</u></u>	

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021****5. Income from investments**

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Interest receivable	76	76	996
	<u>76</u>	<u>76</u>	
Total 2020	996	996	
	<u>996</u>	<u>996</u>	

6. Other incoming resources

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Royalty income	524	524	89
	<u>524</u>	<u>524</u>	
Total 2020	89	89	
	<u>89</u>	<u>89</u>	

7. Expenditure on raising funds**Costs of raising voluntary income**

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Direct costs	1,065	1,065	1,119
	<u>1,065</u>	<u>1,065</u>	
Total 2020	1,119	1,119	
	<u>1,119</u>	<u>1,119</u>	

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021****8. Analysis of expenditure on charitable activities****Summary by fund type**

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Provision of HIV treatment information	106,293	366,289	472,582	481,867
Provision of information on viral hepatitis	8,019	14,927	22,946	20,186
Provision of information on HIV testing, transmission, and prevention of HIV	40,992	51,624	92,616	98,727
Provision of social and non-clinical information on HIV	4,070	64,378	68,448	78,906
	<u>159,374</u>	<u>497,218</u>	<u>656,592</u>	<u>679,686</u>
Total 2020	<u>175,951</u>	<u>503,735</u>	<u>679,686</u>	

9. Analysis of expenditure by activities

	Activities undertaken directly 2021 £	Support costs 2021 £	Total funds 2021 £	Total funds 2020 £
Provision of HIV treatment information	433,890	38,692	472,582	481,867
Provision of information on viral hepatitis	22,645	301	22,946	20,186
Provision of information on HIV testing, transmission, and prevention of HIV	80,862	11,754	92,616	98,727
Provision of social and non-clinical information on HIV	65,259	3,189	68,448	78,906
Total 2021	<u>602,656</u>	<u>53,936</u>	<u>656,592</u>	<u>679,686</u>
Total 2020	<u>624,431</u>	<u>55,255</u>	<u>679,686</u>	

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021****9. Analysis of expenditure by activities (continued)****Analysis of direct costs**

	Provision of HIV treatment information 2021 £	Provision of information on viral hepatitis 2021 £	Provision of information on HIV prevention 2021 £	Provision of social and non-clinical information 2021 £	Total funds 2021 £	Total funds 2020 £
Staff	240,258	1,873	73,252	19,875	335,258	328,053
Subcontractors and consultant writers	95,890	18,827	196	43,708	158,621	196,035
Printing, distribution and storage of resources	5,882	-	-	-	5,882	6,431
Translators	25,525	1,802	893	-	28,220	14,452
Establishment and depreciation	3,460	27	1,064	289	4,840	5,929
Recruitment and training	564	4	173	47	788	-
IT webhosting and support	5,903	46	1,815	492	8,256	12,357
Administration	9,036	66	3,237	848	13,187	31,058
Other	47,052	-	232	-	47,284	28,509
Travel and subsistence	320	-	-	-	320	1,607
Total 2021	433,890	22,645	80,862	65,259	602,656	624,431
Total 2020	442,089	20,186	86,592	75,564	624,431	

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021****9. Analysis of expenditure by activities (continued)****Analysis of support costs**

	Provision of HIV treatment information 2021 £	Provision of information on viral hepatitis 2021 £	Provision of information on HIV prevention 2021 £	Provision of social and non-clinical information 2021 £	Total funds 2021 £	Total funds 2020 £
Staff	36,008	280	10,938	2,968	50,194	49,478
Establishment	568	4	173	47	792	350
IT	971	8	295	80	1,354	1,859
Miscellaneous	1,145	9	348	94	1,596	3,568
Total 2021	38,692	301	11,754	3,189	53,936	55,255
Total 2020	39,778	12,135	3,342	-	55,255	

10. Trustees' remuneration and expenses

During the year, no trustees received any remuneration or other benefits (2020 - £NIL).

During the year ended 31 December 2021, no trustee expenses have been incurred or reimbursed (2020 - £NIL).

11. Staff costs

	2021 £	2020 £
Wages and salaries	334,212	326,688
Social security costs	31,456	31,198
Other pension costs	19,784	19,242
	385,452	377,128

The average number of persons employed by the charity during the year was as follows:

	2021 No.	2020 No.
Office and administration staff	3	3
Production staff	5	5
	8	8

NAM PUBLICATIONS
(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

11. Staff costs (continued)

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2021	2020
	No.	No.
In the band £60,001 - £70,000	1	1

Contributions totalling £3,928 (2020: £3,900) were made to defined contribution pension schemes on behalf of employees whose emoluments exceeds £60,000.

The total remuneration including the value of all monetary employee benefits for key management personnel was £128,515 (2020: £126,385).

12. Taxation

NAM Publications is a registered charity and therefore is not liable to income tax or corporation tax on income derived from its charitable activities, as it falls within the various exemptions available to registered charities.

13. Tangible fixed assets

	Plant and machinery	Fixtures and fittings	Total
	£	£	£
Cost			
At 1 January 2021	16,151	1,250	17,401
Additions	9,841	-	9,841
At 31 December 2021	25,992	1,250	27,242
Depreciation			
At 1 January 2021	10,810	697	11,507
Charge for the year	3,796	83	3,879
At 31 December 2021	14,606	780	15,386
Net book value			
At 31 December 2021	11,386	470	11,856
At 31 December 2020	5,341	553	5,894

NAM PUBLICATIONS
(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

14. Financial instruments

	2021	2020
	£	£
Financial assets		
Financial assets measured at fair value through income and expenditure	829,110	537,508

Financial assets measured at fair value through income and expenditure includes cash at bank.

15. Debtors

	2021	2020
	£	£
Due within one year		
Trade debtors	33,118	135,105
Other debtors	901	5,381
Prepayments and accrued income	15,674	157,348
	49,693	297,834

16. Creditors: Amounts falling due within one year

	2021	2020
	£	£
Trade creditors	45,483	23,619
Other taxation and social security	10,142	9,554
Other creditors	13,989	10,911
Accruals and deferred income	43,046	93,046
	112,660	137,130

17. Retirement benefit schemes

The charity operates a defined contribution pension scheme for all qualifying employees and contributes to the personal pension plans of certain employees. The assets of the schemes are held separately from those of the charity in independently administered funds.

Included in other creditors is an unpaid amount in respect of pension contributions of £5,240 (2020: £1,157).

The charge to the statement of financial activities in respect of defined contribution schemes was £19,784 (2020: £19,242).

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021****18. Deferred income**

Deferred income comprises advanced payments for annual subscriptions for information resources and consultancy services.

	2021	2020
	£	£
Deferred income at 1 January 2021	79,003	81,306
Amounts received in the year	711,347	761,939
Amounts credited to SOFA	(676,623)	(805,977)
Movement in trade debtors	(94,531)	41,735
Deferred income at 31 December 2021	19,196	79,003

19. Independent examiner's remuneration

The independent examiner's remuneration amounts to an independent examiner fee of £5,500 (2020 - £4,700).

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021****20. Statement of funds****Statement of funds - current year**

	Balance at 1 January 2021 £	Income £	Expenditure £	Balance at 31 December 2021 £
Unrestricted funds				
General Funds - all funds	607,900	227,622	(160,439)	675,083
Restricted funds				
1. Fast Track Cities London Improvement Collaborative Fund	15,499	54,000	(53,999)	15,500
2. Gilead Sciences Europe	16,505	66,021	(49,515)	33,011
3. Gilead Sciences Europe	-	60,000	(35,470)	24,530
4. Gilead Sciences Europe	-	41,176	(30,881)	10,295
5. Merck	-	28,536	(26,624)	1,912
6. ViiV Healthcare	-	150,104	(150,104)	-
Others below £20,000	64,202	104,091	(150,625)	17,668
	96,206	503,928	(497,218)	102,916
Total of funds	704,106	731,550	(657,657)	777,999

Unrestricted funds are funds that the trustees are free to spend on any charitable activities.

Restricted funds relate to voluntary income received towards the charity's activities where the use is restricted by the conditions imposed by the grant providers. The majority of restricted income is spent in the same year that it is received. A description of our material restricted funds is given below.

1. Fast Track Cities London Improvement Fund: Grant towards early diagnosis and testing in Black African communities, training a group of Positive Champions, creating educational videos and conducting on the spot testing in a range of locations in south east London.

2. Gilead Sciences Europe: Grant towards daily HIV prevention and treatment news stories, e-bulletins and creation of social media content.

3. Gilead Sciences UK: Grant towards HIV Lens an interactive online mapping tool that visualises the impact of the HIV epidemic on communities across England..

4. Gilead Sciences Europe: Grant towards multi-lingual HIV conference news and e-bulletins for clinicians, healthcare staff, community-based organisations and patients.

5. Merck: Grant towards NAM aidsmap's PrEP in Europe Initiative..

6. ViiV Healthcare: Grant towards NAM aidsmap's PrEP in Europe Initiative, multi-lingual HIV conference news coverage, aidsmapLIVES broadcasts, Emerging Voices programme for new writers, and Sexual Health and HIV Policy EURObulletin..

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021****20. Statement of funds (continued)****Statement of funds - prior year**

	Balance at 1 January 2020 £	Income £	Expenditure £	Balance at 31 December 2020 £
Unrestricted funds				
General Funds - all funds	445,070	339,900	(177,070)	607,900
Restricted funds				
1. Fast Track Cities London Improvement Collaborative Fund	-	54,000	(38,501)	15,499
2. Gilead Sciences Europe	-	66,021	(49,516)	16,505
3. Gilead Sciences Europe	34,313	-	(34,313)	-
4. Gilead Sciences Europe	-	30,000	(15,193)	14,807
5. Public Health England	-	25,988	(14,825)	11,163
6. Merck	-	30,000	(30,000)	-
7. National Lottery	-	20,278	(10,139)	10,139
8. ViiV Healthcare	-	60,000	(60,000)	-
9. ViiV Healthcare	-	28,628	(28,628)	-
Others below £20,000	99,551	151,162	(222,620)	28,093
	<u>133,864</u>	<u>466,077</u>	<u>(503,735)</u>	<u>96,206</u>
Total of funds	<u><u>578,934</u></u>	<u><u>805,977</u></u>	<u><u>(680,805)</u></u>	<u><u>704,106</u></u>

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021****21. Summary of funds****Summary of funds - current year**

	Balance at 1 January 2021 £	Income £	Expenditure £	Balance at 31 December 2021 £
General funds	607,900	227,622	(160,439)	675,083
Restricted funds	96,206	503,928	(497,218)	102,916
	<u>704,106</u>	<u>731,550</u>	<u>(657,657)</u>	<u>777,999</u>

Summary of funds - prior year

	Balance at 1 January 2020 £	Income £	Expenditure £	Balance at 31 December 2020 £
General funds	445,070	339,900	(177,070)	607,900
Restricted funds	133,864	466,077	(503,735)	96,206
	<u>578,934</u>	<u>805,977</u>	<u>(680,805)</u>	<u>704,106</u>

22. Analysis of net assets between funds**Analysis of net assets between funds - current year**

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £
Tangible fixed assets	11,856	-	11,856
Current assets	774,986	102,916	877,902
Creditors due within one year	(111,759)	-	(111,759)
Total	<u>675,083</u>	<u>102,916</u>	<u>777,999</u>

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021****22. Analysis of net assets between funds (continued)****Analysis of net assets between funds - prior year**

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Tangible fixed assets	5,894	-	5,894
Current assets	739,136	96,206	835,342
Creditors due within one year	(137,130)	-	(137,130)
Total	607,900	96,206	704,106

23. Reconciliation of net movement in funds to net cash flow from operating activities

	2021 £	2020 £
Net income for the year (as per Statement of Financial Activities)	73,893	125,172
Adjustments for:		
Depreciation charges	3,879	1,878
Investment income	(76)	(996)
Decrease/(increase) in debtors	248,141	(156,944)
Increase/(decrease) in creditors	35,337	4,190
Increase/(decrease) in deferred income	(59,807)	(2,303)
Net cash provided by/(used in) operating activities	301,367	(29,003)

24. Analysis of cash and cash equivalents

	2021 £	2020 £
Cash in hand	829,110	537,508
Total cash and cash equivalents	829,110	537,508

NAM PUBLICATIONS**(A COMPANY LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021****25. Analysis of changes in net debt**

	At 1 January 2021 £	Cash flows £	At 31 December 2021 £
Cash at bank and in hand	537,508	291,602	829,110
	537,508	291,602	829,110

26. Operating lease commitments

The charity had no commitments under non-cancellable operating leases at 31 December 2021.

27. Related party transactions

There were no disclosable related party transactions during the year (2020 - none).